Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2005

Open Access 01-12-2005 | Research article

Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease

Authors: Daniëlle Hof, Kalok Cheung, Dirk-Jan RAM de Rooij, Frank H van den Hoogen, Ger JM Pruijn, Walther J van Venrooij, Jos MH Raats

Published in: Arthritis Research & Therapy | Issue 2/2005

Login to get access

Abstract

Modifications occurring on autoantigens during cell death have been proposed to have a role in the initiation of autoimmune diseases. Patients suffering from mixed connective tissue disease (MCTD) produce autoantibodies directed to U1 small nuclear ribonucleoprotein (snRNP), and antibodies against a 70 kDa protein component, the U1-70K (70K) protein, are the most prominent. During apoptosis, 70K is cleaved by caspase-3 to a 40 kDa product, which remains associated with the complex. Autoantibodies preferentially recognizing the apoptotic form of 70K have been described previously, and an apoptosis-specific epitope on 70K has been identified. This study shows that 29 of 53 (54%) MCTD sera preferentially recognize the apoptotic form of 70K over intact 70K. Moreover, we show that antibodies directed to an apoptosis-specific epitope on 70K are more specifically associated with MCTD than other anti-70K antibodies, suggesting that apoptotic 70K is a better antigen for the detection of these antibodies in MCTD patients. Longitudinal analysis of 12 MCTD patients showed in several patients that early sera are relatively enriched with antibodies recognizing an apoptosis-specific epitope, and that the levels of these apoptosis-specific antibodies decrease in time. These findings indicate that the early detection of apoptotic 70K is of considerable interest for anti-U1 snRNP-positive patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR: Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972, 52: 148-159. 10.1016/0002-9343(72)90064-2.CrossRefPubMed Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR: Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972, 52: 148-159. 10.1016/0002-9343(72)90064-2.CrossRefPubMed
2.
go back to reference Smolen JS, Steiner G: Mixed connective tissue disease: to be or not to be?. Arthritis Rheum. 1998, 41: 768-777. 10.1002/1529-0131(199805)41:5<768::AID-ART3>3.0.CO;2-Z.CrossRefPubMed Smolen JS, Steiner G: Mixed connective tissue disease: to be or not to be?. Arthritis Rheum. 1998, 41: 768-777. 10.1002/1529-0131(199805)41:5<768::AID-ART3>3.0.CO;2-Z.CrossRefPubMed
3.
go back to reference Lerner MR, Steitz JA: Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci USA. 1979, 76: 5495-5499.PubMedCentralCrossRefPubMed Lerner MR, Steitz JA: Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc Natl Acad Sci USA. 1979, 76: 5495-5499.PubMedCentralCrossRefPubMed
4.
5.
go back to reference Lührmann R, Kastner B, Bach M: Structure of spliceosomal snRNPs and their role in pre mRNA splicing. Biochim Biophys Acta. 1990, 1087: 265-292.CrossRefPubMed Lührmann R, Kastner B, Bach M: Structure of spliceosomal snRNPs and their role in pre mRNA splicing. Biochim Biophys Acta. 1990, 1087: 265-292.CrossRefPubMed
6.
go back to reference Klein Gunnewiek JM, van de Putte LB, van Venrooij WJ: The U1 snRNP complex: an autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol. 1997, 15: 549-560.PubMed Klein Gunnewiek JM, van de Putte LB, van Venrooij WJ: The U1 snRNP complex: an autoantigen in connective tissue diseases. An update. Clin Exp Rheumatol. 1997, 15: 549-560.PubMed
7.
go back to reference van Venrooij WJ, Pruijn GJ: Ribonucleoprotein complexes as autoantigens. Curr Opin Immunol. 1995, 7: 819-824. 10.1016/0952-7915(95)80054-9.CrossRefPubMed van Venrooij WJ, Pruijn GJ: Ribonucleoprotein complexes as autoantigens. Curr Opin Immunol. 1995, 7: 819-824. 10.1016/0952-7915(95)80054-9.CrossRefPubMed
8.
go back to reference Brahms H, Raker VA, van Venrooij WJ, Lührmann R: A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E-F-G complex but not in their denatured states. Arthritis Rheum. 1997, 40: 672-682.CrossRefPubMed Brahms H, Raker VA, van Venrooij WJ, Lührmann R: A major, novel systemic lupus erythematosus autoantibody class recognizes the E, F, and G Sm snRNP proteins as an E-F-G complex but not in their denatured states. Arthritis Rheum. 1997, 40: 672-682.CrossRefPubMed
9.
go back to reference Rodenburg RJT, Raats JMH, Pruijn GJM, van Venrooij WJ: Cell death: a trigger of autoimmunity?. BioEssays. 2000, 22: 1-10. 10.1002/1521-1878(200007)22:7<627::AID-BIES5>3.0.CO;2-K.CrossRef Rodenburg RJT, Raats JMH, Pruijn GJM, van Venrooij WJ: Cell death: a trigger of autoimmunity?. BioEssays. 2000, 22: 1-10. 10.1002/1521-1878(200007)22:7<627::AID-BIES5>3.0.CO;2-K.CrossRef
10.
go back to reference Utz PJ, Anderson P: Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum. 1998, 41: 1152-1160. 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L.CrossRefPubMed Utz PJ, Anderson P: Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum. 1998, 41: 1152-1160. 10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L.CrossRefPubMed
11.
go back to reference Wu X, Molinaro C, Johnson N, Casiano CA: Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum. 2001, 44: 2642-2652. 10.1002/1529-0131(200111)44:11<2642::AID-ART444>3.0.CO;2-8.CrossRefPubMed Wu X, Molinaro C, Johnson N, Casiano CA: Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum. 2001, 44: 2642-2652. 10.1002/1529-0131(200111)44:11<2642::AID-ART444>3.0.CO;2-8.CrossRefPubMed
13.
go back to reference Rosen A, Casciola-Rosen LA: Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ. 1999, 6: 6-12. 10.1038/sj.cdd.4400460.CrossRefPubMed Rosen A, Casciola-Rosen LA: Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ. 1999, 6: 6-12. 10.1038/sj.cdd.4400460.CrossRefPubMed
14.
go back to reference Casciola-Rosen LA, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A: Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med. 1996, 183: 1957-1964. 10.1084/jem.183.5.1957.CrossRefPubMed Casciola-Rosen LA, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A: Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med. 1996, 183: 1957-1964. 10.1084/jem.183.5.1957.CrossRefPubMed
15.
go back to reference Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A: Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem. 1994, 269: 30757-30760.PubMed Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A: Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem. 1994, 269: 30757-30760.PubMed
16.
go back to reference Greidinger EL, Hoffman RW: The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B' /B proteins as predominant U1 RNP immunogens. Arthritis Rheum. 2001, 44: 368-375. 10.1002/1529-0131(200102)44:2<368::AID-ANR55>3.0.CO;2-6.CrossRefPubMed Greidinger EL, Hoffman RW: The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B' /B proteins as predominant U1 RNP immunogens. Arthritis Rheum. 2001, 44: 368-375. 10.1002/1529-0131(200102)44:2<368::AID-ANR55>3.0.CO;2-6.CrossRefPubMed
17.
go back to reference Degen WGJ, van Aarssen Y, Pruijn GJM, Utz PJ, van Venrooij WJ: The fate of U1 snRNP during anti-Fas induced apoptosis: specific cleavage of the U1 snRNA molecule. Cell Death Differ. 2000, 7: 70-79. 10.1038/sj.cdd.4400617.CrossRefPubMed Degen WGJ, van Aarssen Y, Pruijn GJM, Utz PJ, van Venrooij WJ: The fate of U1 snRNP during anti-Fas induced apoptosis: specific cleavage of the U1 snRNA molecule. Cell Death Differ. 2000, 7: 70-79. 10.1038/sj.cdd.4400617.CrossRefPubMed
18.
go back to reference Greidinger EL, Foecking MF, Ranatunga S, Hoffman RW: Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis Rheum. 2002, 46: 1264-1269. 10.1002/art.10211.CrossRefPubMed Greidinger EL, Foecking MF, Ranatunga S, Hoffman RW: Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. Arthritis Rheum. 2002, 46: 1264-1269. 10.1002/art.10211.CrossRefPubMed
19.
go back to reference Greidinger EL, Foecking MF, Magee J, Wilson L, Ranatunga S, Ortmann RA, Hoffman RW: A major B cell epitope present on the apoptotic but not the intact form of the U1-70-kDa ribonucleoprotein autoantigen. J Immunol. 2004, 172: 709-716.CrossRefPubMed Greidinger EL, Foecking MF, Magee J, Wilson L, Ranatunga S, Ortmann RA, Hoffman RW: A major B cell epitope present on the apoptotic but not the intact form of the U1-70-kDa ribonucleoprotein autoantigen. J Immunol. 2004, 172: 709-716.CrossRefPubMed
20.
go back to reference Greidinger EL, Foecking MF, Schafermeyer KR, Bailey CW, Primm SL, Lee DR, Hoffman RW: T cell immunity in connective tissue disease patients targets the RNA binding domain of the U1-70kDa small nuclear ribonucleoprotein. J Immunol. 2002, 169: 3429-3437.CrossRefPubMed Greidinger EL, Foecking MF, Schafermeyer KR, Bailey CW, Primm SL, Lee DR, Hoffman RW: T cell immunity in connective tissue disease patients targets the RNA binding domain of the U1-70kDa small nuclear ribonucleoprotein. J Immunol. 2002, 169: 3429-3437.CrossRefPubMed
21.
go back to reference Hoet RMA, Koornneef I, de Rooij DJ, van de Putte LB, van Venrooij WJ: Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum. 1992, 35: 1202-1210.CrossRefPubMed Hoet RMA, Koornneef I, de Rooij DJ, van de Putte LB, van Venrooij WJ: Changes in anti-U1 RNA antibody levels correlate with disease activity in patients with systemic lupus erythematosus overlap syndrome. Arthritis Rheum. 1992, 35: 1202-1210.CrossRefPubMed
22.
go back to reference ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990, 33: 634-643.CrossRefPubMed ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990, 33: 634-643.CrossRefPubMed
23.
go back to reference Billings PB, Allen RW, Jensen FC, Hoch SO: Anti-RNP monoclonal antibodies derived from a mouse strain with lupus-like autoimmunity. J Immunol. 1982, 128: 1176-1180.PubMed Billings PB, Allen RW, Jensen FC, Hoch SO: Anti-RNP monoclonal antibodies derived from a mouse strain with lupus-like autoimmunity. J Immunol. 1982, 128: 1176-1180.PubMed
24.
go back to reference Degen WGJ, Pieffers M, Welin-Henriksson E, van Venrooij WJ, Raats JMH: Characterization of recombinant human autoantibody fragments directed toward the autoantigenic U1-70K protein. Eur J Immunol. 2000, 30: 3029-3038. 10.1002/1521-4141(200010)30:10<3029::AID-IMMU3029>3.0.CO;2-J.CrossRefPubMed Degen WGJ, Pieffers M, Welin-Henriksson E, van Venrooij WJ, Raats JMH: Characterization of recombinant human autoantibody fragments directed toward the autoantigenic U1-70K protein. Eur J Immunol. 2000, 30: 3029-3038. 10.1002/1521-4141(200010)30:10<3029::AID-IMMU3029>3.0.CO;2-J.CrossRefPubMed
25.
go back to reference Margaux J, Hayem G, Palazzo E, Chazerain P, De Bandt M, Haim T, Kahn MF, Meyer O: Clinical usefulness of antibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus. Rev Rhum Engl Ed. 1998, 65: 378-386.PubMed Margaux J, Hayem G, Palazzo E, Chazerain P, De Bandt M, Haim T, Kahn MF, Meyer O: Clinical usefulness of antibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus. Rev Rhum Engl Ed. 1998, 65: 378-386.PubMed
26.
go back to reference St Clair EW, Query CC, Bentley R, Keene JD, Polisson RP, Allen NB, Caldwell DS, Rice JR, Cox C, Pisetsky DS: Expression of autoantibodies to recombinant (U1) RNP-associated 70K antigen in systemic lupus erythematosus. Clin Immunol Immunopathol. 1990, 54: 266-280. 10.1016/0090-1229(90)90088-8.CrossRefPubMed St Clair EW, Query CC, Bentley R, Keene JD, Polisson RP, Allen NB, Caldwell DS, Rice JR, Cox C, Pisetsky DS: Expression of autoantibodies to recombinant (U1) RNP-associated 70K antigen in systemic lupus erythematosus. Clin Immunol Immunopathol. 1990, 54: 266-280. 10.1016/0090-1229(90)90088-8.CrossRefPubMed
27.
go back to reference Hassan AB, Gunnarsson I, Karlsson G, Klareskog L, Forslid J, Lundberg IE: Longitudinal study of interleukin-10, tumor necrosis factor-alpha, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease. Scand J Rheumatol. 2001, 30: 282-289. 10.1080/030097401753180363.CrossRefPubMed Hassan AB, Gunnarsson I, Karlsson G, Klareskog L, Forslid J, Lundberg IE: Longitudinal study of interleukin-10, tumor necrosis factor-alpha, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease. Scand J Rheumatol. 2001, 30: 282-289. 10.1080/030097401753180363.CrossRefPubMed
28.
go back to reference Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004, 50: 380-386. 10.1002/art.20018.CrossRefPubMed Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004, 50: 380-386. 10.1002/art.20018.CrossRefPubMed
29.
go back to reference Rantapää-Dahlqvist S, De Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002/art.11223.CrossRefPubMed Rantapää-Dahlqvist S, De Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002/art.11223.CrossRefPubMed
30.
go back to reference Malmegrim KC, Pruijn GJ, van Venrooij WJ: The fate of the U1 snRNP autoantigen during apoptosis: implications for systemic autoimmunity. Isr Med Assoc J. 2002, 4: 706-712.PubMed Malmegrim KC, Pruijn GJ, van Venrooij WJ: The fate of the U1 snRNP autoantigen during apoptosis: implications for systemic autoimmunity. Isr Med Assoc J. 2002, 4: 706-712.PubMed
31.
go back to reference Greidinger EL, Casciola RL, Morris SM, Hoffman RW, Rosen A: Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations. Arthritis Rheum. 2000, 43: 881-888. 10.1002/1529-0131(200004)43:4<881::AID-ANR20>3.0.CO;2-G.CrossRefPubMed Greidinger EL, Casciola RL, Morris SM, Hoffman RW, Rosen A: Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations. Arthritis Rheum. 2000, 43: 881-888. 10.1002/1529-0131(200004)43:4<881::AID-ANR20>3.0.CO;2-G.CrossRefPubMed
32.
go back to reference Casciola-Rosen LA, Andrade F, Ulanet D, Bang Wong W, Rosen A: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med. 1999, 190: 815-826. 10.1084/jem.190.6.815.PubMedCentralCrossRefPubMed Casciola-Rosen LA, Andrade F, Ulanet D, Bang Wong W, Rosen A: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med. 1999, 190: 815-826. 10.1084/jem.190.6.815.PubMedCentralCrossRefPubMed
Metadata
Title
Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease
Authors
Daniëlle Hof
Kalok Cheung
Dirk-Jan RAM de Rooij
Frank H van den Hoogen
Ger JM Pruijn
Walther J van Venrooij
Jos MH Raats
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1490

Other articles of this Issue 2/2005

Arthritis Research & Therapy 2/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine